-
Tytuł:
-
Genome instability and pressure on non-homologous end joining drives chemotherapy resistance via a DNA repair crisis switch in triple negative breast cancer.
-
Autorzy:
-
Wiegmans AP; Queensland University of Technology (QUT), Cancer and Ageing Research Program, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Translational Research Institute, Woolloongabba QLD 4121, Australia.
Ward A; School of Medicine, University of Queensland, St Lucia, QLD Australia.
Ivanova E; Queensland University of Technology (QUT), Cancer and Ageing Research Program, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Translational Research Institute, Woolloongabba QLD 4121, Australia.
Duijf PHG; Queensland University of Technology (QUT), Cancer and Ageing Research Program, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Translational Research Institute, Woolloongabba QLD 4121, Australia.
Adams MN; Queensland University of Technology (QUT), Cancer and Ageing Research Program, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Translational Research Institute, Woolloongabba QLD 4121, Australia.
Najib IM; Queensland University of Technology (QUT), Cancer and Ageing Research Program, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Translational Research Institute, Woolloongabba QLD 4121, Australia.
Van Oosterhout R; Tumor Microenvironment Laboratory, QIMR Berghofer, Herston Rd, Herston, QLD 4006, Australia.
Sadowski MC; Queensland University of Technology (QUT), Cancer and Ageing Research Program, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Translational Research Institute, Woolloongabba QLD 4121, Australia.
Kelly G; Tumor Microenvironment Laboratory, QIMR Berghofer, Herston Rd, Herston, QLD 4006, Australia.
Morrical SW; Department of Biochemistry, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA.
O'Byrne K; Queensland University of Technology (QUT), Cancer and Ageing Research Program, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Translational Research Institute, Woolloongabba QLD 4121, Australia.
Lee JS; School of Medicine, University of Queensland, St Lucia, QLD Australia.
Richard DJ; Queensland University of Technology (QUT), Cancer and Ageing Research Program, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Translational Research Institute, Woolloongabba QLD 4121, Australia.
-
Źródło:
-
NAR cancer [NAR Cancer] 2021 Jun 15; Vol. 3 (2), pp. zcab022. Date of Electronic Publication: 2021 Jun 15 (Print Publication: 2021).
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Oxford : Oxford University Press, [2019]-
-
References:
-
JAMA. 2011 May 11;305(18):1873-81. (PMID: 21558518)
Tumour Biol. 2016 Aug;37(8):11017-24. (PMID: 26894602)
Cells. 2019 Aug 22;8(9):. (PMID: 31443516)
Bioorg Med Chem Lett. 2017 Jul 15;27(14):3096-3100. (PMID: 28545975)
Oncol Lett. 2018 Sep;16(3):3757-3769. (PMID: 30127986)
Int J Mol Sci. 2018 Apr 13;19(4):. (PMID: 29652801)
Mol Cell. 2015 Nov 19;60(4):547-60. (PMID: 26590714)
Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15848-53. (PMID: 18840682)
Cell Cycle. 2008 Jun 15;7(12):1726-31. (PMID: 18583938)
Sci Rep. 2018 Jan 17;8(1):967. (PMID: 29343829)
J Clin Invest. 2011 Jul;121(7):2750-67. (PMID: 21633166)
Sci Rep. 2019 Aug 2;9(1):11227. (PMID: 31375703)
Genome Res. 2015 Mar;25(3):316-27. (PMID: 25650244)
Nat Rev Mol Cell Biol. 2008 Aug;9(8):616-27. (PMID: 18594563)
Oncotarget. 2014 May 30;5(10):3261-72. (PMID: 24811120)
NPJ Breast Cancer. 2016 Nov 16;2:16036. (PMID: 28721389)
Cancer Res. 2002 Jul 1;62(13):3598-602. (PMID: 12097259)
EMBO Rep. 2006 Feb;7(2):219-24. (PMID: 16322760)
Nat Med. 2018 May;24(5):628-637. (PMID: 29713086)
Pathol Biol (Paris). 2006 May;54(4):185-93. (PMID: 16563661)
Korean J Physiol Pharmacol. 2013 Aug;17(4):291-7. (PMID: 23946688)
Histopathology. 2009 Dec;55(6):696-704. (PMID: 20002770)
Cancer Cell. 2003 Apr;3(4):387-402. (PMID: 12726864)
Cell Rep. 2017 May 16;19(7):1304-1312. (PMID: 28514651)
Cancer Treat Rev. 2015 Jan;41(1):35-45. (PMID: 25467108)
Cell. 2018 May 3;173(4):879-893.e13. (PMID: 29681456)
Nat Commun. 2014;5:3361. (PMID: 24553445)
J Clin Oncol. 2016 Dec 20;34(36):4354-4361. (PMID: 27998224)
Ann Oncol. 2018 Apr 1;29(4):895-902. (PMID: 29365031)
Hum Mutat. 2014 Jun;35(6):756-65. (PMID: 24700732)
Cell Cycle. 2013 Jun 15;12(12):1861-7. (PMID: 23708520)
Cancer Res. 2019 May 1;79(9):2392-2403. (PMID: 30862715)
Nat Rev Cancer. 2008 Mar;8(3):193-204. (PMID: 18256616)
Genes (Basel). 2016 Aug 19;7(8):. (PMID: 27548226)
BMC Genomics. 2016 Jun 09;17:442. (PMID: 27277198)
Cell Rep. 2016 Jun 21;15(12):2679-91. (PMID: 27292643)
PLoS One. 2015 Jan 30;10(1):e0116747. (PMID: 25635866)
J Natl Cancer Inst. 2020 Jul 1;112(7):708-719. (PMID: 31665482)
Cancers (Basel). 2017 Jul 06;9(7):. (PMID: 28684677)
Cancer Res. 2002 Jan 1;62(1):219-25. (PMID: 11782381)
Cancer Res. 2007 Oct 15;67(20):9658-65. (PMID: 17942895)
Breast Cancer Res Treat. 2018 Apr;168(3):625-630. (PMID: 29275435)
Nat Rev Genet. 2014 Sep;15(9):585-98. (PMID: 24981601)
EMBO Mol Med. 2018 Dec;10(12):. (PMID: 30377213)
Breast Cancer Res. 2020 Oct 15;22(1):107. (PMID: 33059724)
Nat Rev Mol Cell Biol. 2003 Sep;4(9):712-20. (PMID: 14506474)
-
Entry Date(s):
-
Date Created: 20210728 Latest Revision: 20220830
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC8210242
-
DOI:
-
10.1093/narcan/zcab022
-
PMID:
-
34316709
-
Chemotherapy is used as a standard-of-care against cancers that display high levels of inherent genome instability. Chemotherapy induces DNA damage and intensifies pressure on the DNA repair pathways that can lead to deregulation. There is an urgent clinical need to be able to track the emergence of DNA repair driven chemotherapy resistance and tailor patient staging appropriately. There have been numerous studies into chemoresistance but to date no study has elucidated in detail the roles of the key DNA repair components in resistance associated with the frontline clinical combination of anthracyclines and taxanes together. In this study, we hypothesized that the emergence of chemotherapy resistance in triple negative breast cancer was driven by changes in functional signaling in the DNA repair pathways. We identified that consistent pressure on the non-homologous end joining pathway in the presence of genome instability causes failure of the key kinase DNA-PK, loss of p53 and compensation by p73. In-turn a switch to reliance on the homologous recombination pathway and RAD51 recombinase occurred to repair residual double strand DNA breaks. Further we demonstrate that RAD51 is an actionable target for resensitization to chemotherapy in resistant cells with a matched gene expression profile of resistance highlighted by homologous recombination in clinical samples.
(© The Author(s) 2021. Published by Oxford University Press on behalf of NAR Cancer.)
